FEASIBILITY OF BORON NEUTRON CAPTURE THERAPY USING PARTICLE ACCELERATOR

核工业工人，测井工人， 和机组人员，包括大量的中子， 能量低于100 keV。 此外，正常组织剂量从 硼中子俘获疗法将主要来自低能量 中子 微剂量学理论预测， 生物学效应（RBE）的中子与能量低于约 350 keV相比，更高的能量中子;这是因为 低能中子与生物材料的相互作用 为了使质子在具有降低的LET（停止）的组织中反冲， 功率），并且降低范围。 基于这样的考虑， 有限的生物数据，目前分配的辐射权重 中子的质量因子（以前称为质量因子）， 10 keV至100 keV的能量小于更高能量的中子。 通过 相反，一些报告表明， 24 keV中子与快中子相似。 两种细胞 确定了存活率和致癌转化诱导， C3 H10 T1/2细胞暴露于两种低能中子束， 40和70 keV的剂量平均能量，并与 高能中子和X射线 结果与 目前推荐的低能中子的降低值 辐射权重因子，与快中子相比。

Neutron exposure of workers in the nuclear industry, well loggers, and airline crew members, includes significant doses of neutrons with energies below 100 keV. In addition, the normal tissue dose from boron neutron capture therapy will largely be from low-energy neutrons. Microdosimetric theory predicts decreasing relative biological effectiveness (RBE) for neutrons with energies below about 350 keV compared to that for higher energy neutrons; this is because interactions of low-energy neutrons with biological material give rise to recoil protons in tissue that have both decreasing LET (stopping power), and decreasing range. Based on such considerations, and limited biological data, the currently assigned radiation weighting factor (previously the quality factor) for neutrons with energies from 10 keV to 100 keV is less than that for higher-energy neutrons. By contrast, a few reports have suggested that the biological effects of 24 keV neutrons is similar to that of fast neutrons. Both cell survival and oncogenic transformation induction were determined for C3H10T1/2 cells exposed to two low-energy neutron beams with dose-averaged mean energies of 40 and 70 keV, and compared to that for higher energy neutrons and X rays. The results were consistent with the currently recommended decreased values for low-energy neutron radiation weighting factors, compared to fast neutrons.